Strategy for managing patients with severe cases of rosacea

Cover Page

Abstract


The article presents 3 clinical observations of women of 51, 55 and 57 years old with severe rosacea, who reached the state of remission after a prolonged course of systemic therapy with low doses of isotretinoin. Cumulative dose of isotretinoin for persistent clinical remission was 46.4 mg/kg of weight, 17.6 mg/kg, 12.6 mg/kg respectively. Difficulties related to the subjective perception of patients of his condition has limited the possibility of increasing daily dose of isotretinoin, and the lack of result from the previous therapy with basic medications has made isotretinoin a drug of choice.

I. G. Sergeyeva

Novosibirsk State National Research University

Author for correspondence.
Email: i_g_sergeeva@mail.ru

Russian Federation

Yu. M. Krinitsyna

Research Institute of regional Pathology and Pathomorphology

Email: noemail@neicon.ru

Russian Federation

  1. Araviyskaya E.R.. Samtsov A.V. Federalnyye klinicheskiye rekomendatsii po vedeniyu bolnykh rozatsea. Moskva; 2015
  2. Rademaker M. Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. The Australasian Journal Of Dermatology 2016; 20: 1440-0960.
  3. Sbidian E., Vicaut É., Chosidow O. et al. A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea. The Journal Of Investigative Dermatology 2016; 136 (6): 1124-1129.
  4. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed 2003; 2: 43-47.
  5. Egeberg A., Hansen P., Gislason G., Thyssen J. Patients with Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Dermatology 2016; 232 (2): 208-213.
  6. Monakhov S.A. Rozatsea (metodicheskoye posobiye dlya vrachey). M; 2016.
  7. Samtsov A.V. Gorbunov Yu.G. Izotretinoin v lechenii rozatsea. Vestn dermatol venerol 2012; (4): 102-104

Views

Abstract - 95

PDF (Russian) - 37

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies